Secondary analysis of RTOG 0247 demonstrates favorable OS rates for rectal cancer patients
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a study.
The affiliation of Eun Kyung Choi was listed incorrectly. It has been corrected to exclude one of the original affiliation (Institute for Innovative Cancer Research) and include ‘University of Ulsan, College of Medicine’ in the last affiliation. The correct list of authors and affiliations are listed below. The authors regret the error.
A shorter radiotherapy protocol for treating prostate cancer is comparable...Read more on AuntMinnie.comRelated Reading: ASTRO: AI's rad therapy future is in predicting outcomes ASTRO: SBRT works well for less risky prostate cancer ASTRO releases new prostate radiation therapy guideline SNMMI: Early prostate cancer therapy extends lives Hypofractionated RT works for prostate cancer
(NIH/National Institute of Neurological Disorders and Stroke) In a study of mice and human brain tumors researchers at the University of the Michigan, Ann Arbor, searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others. The results suggested that certain patients' tumor cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation. The researchers then showed that combining radiation therapy with cancer drugs designed to block DNA repair may be an effective treatment strategy.
Lupron (leuprolide acetate) is a type of hormone therapy for people with prostate cancer. Lupron is an injection drug, and doctors often prescribe it in combination with radiation therapy or surgery. As it lowers a person ’s testosterone levels, Lupron can cause a range of side effects. Learn more here.
Authors: Ren Y, Zhang Z, Shang L, You X Abstract BACKGROUND Metastatic Ewing's sarcoma (ES) of bone has a poor prognosis. Because there have been few previous studies on the prognostic factors and clinical outcome in patients with ES who have metastases at presentation, the aim of this study was to use the Surveillance, Epidemiology, and End Results (SEER) database to compare the clinical outcome following single and combined radiation treatment and surgery. MATERIAL AND METHODS The SEER database was used to identify patients with ES who presented with bone involvement and metastasis between 1973 to 2015. Prognosti...
Radiation therapy remains an important therapeutic modality, especially for those patients who are not candidates for radical resection. Many strategies have been developed to increase the radiosensitivity of ...
AbstractPurposeWe developed a heart atlas for breast radiation therapy and evaluated the influence of education on intra and inter-observer similarity, and cardiac dose reporting.Materials and methodsThe data of 16 left breast cancer patients were analyzed. Eight observers delineated heart and cardiac subunits [left (LCA) and right (RCA) coronary arteries, left anterior descending artery (LAD), bilateral atrium and ventricles] before the education. A radiologist and radiation oncologist developed the atlas and delineated the gold standard (GS) volumes. Observers repeated the delineation after education. RT plans were made ...
BackgroundThe role of thoracic radiation therapy (TRT) after chemotherapy (CHT) in extensive ‐stage small cell lung cancer (ES‐SCLC) has not been well defined. We investigated whether intensity‐modulated radiotherapy (IMRT) improves outcomes in ES‐SCLC after CHT compared to CHT alone.MethodsA total of 292 patients who reached a complete response (CR), partial response (PR), or stable disease (SD) after CHT were assigned into groups: CHT + TRT and CHT alone. Propensity score matching was used to balance patient groups (n = 72 each).ResultsThe five ‐year overall survival (OS: 12.3% vs. 3.6%;P
ConclusionsTiming for oral rehabilitation may differ depending on the treatment modality followed for mandibular tumors in the patient with oral cancer. However, most patients in this cohort underwent rehabilitation with removable mandibular resection prostheses regardless of the timing of care. Endosseous implants were used infrequently, but research is needed to better understand their potential role and indication in the patient with oral cancer.
ConclusionsBased on indirect comparisons, no differences in clinical outcomes were observed among diverse APBI techniques in published clinical trials that formally compared WBI to APBI. However wide confidence intervals and high risk of inconsistency precluded a sound conclusion. Further head-to-head clinical trials comparing different APBI techniques are required to confirm our findings. Studies comparing different techniques using individual participant data and/or real-life data from population-based studies/registries could also provide more robust results.